RNA News and Research

RSS

Ribonucleic acid (RNA) is a biologically important type of molecule that consists of a long chain of nucleotide units. Each nucleotide consists of a nitrogenous base, a ribose sugar, and a phosphate.

Regulus Therapeutics, GSK announce new collaboration on microRNA therapeutics targeting microRNA-122

Regulus Therapeutics Inc. today announced the establishment of a new collaboration with GlaxoSmithKline (GSK) to develop and commercialize microRNA therapeutics targeting microRNA-122 in all fields with Hepatitis C Viral infection (HCV) as the lead indication. Under the terms of the new collaboration, Regulus will receive additional upfront and early-stage milestone payments with the potential to earn more than $150 million in miR-122-related combined payments, and tiered royalties up to double digits on worldwide sales of products.

25 Feb 2010

α-defensins1-3 may be potential prophylactic agents in treatment of HIV / AIDS

HIV/AIDS remains one of the world's most significant public health challenges, particularly in developing countries. The Human Immunodeficiency Virus (HIV-1), the variant responsible for the pandemic, has the ability to infect different cell types such as T cells, macrophages and dendritic cells (DC). These latter cells are crucial in the defense against infectious agents and play a major role in viral pathogenesis.

25 Feb 2010

Anadys Pharmaceuticals' ANA598 combination demonstrates 73% cEVR in ongoing Phase II study for HCV

Anadys Pharmaceuticals, Inc. today announced preliminary results from an ongoing Phase II study demonstrating that 73% of hepatitis C patients treated with 200 mg ANA598 twice daily in combination with pegylated interferon and ribavirin (SOC) achieved undetectable levels of virus (<15 IU/mL) at week 12, known as complete Early Virological Response or cEVR.

25 Feb 2010

Genetic test for autism: Transgenomic licenses exclusive intellectual property from IntegraGen

Transgenomic, Inc. announced today that it has licensed on an exclusive U.S. basis intellectual property from IntegraGen SA that will enable Transgenomic to develop and commercialize a genetic test designed to assess the risk of autism in children who have older siblings diagnosed with an autism spectrum disorder. Under the agreement Transgenomic will develop the test in the Company's CAP-accredited and CLIA-certified laboratory, and anticipates launching the new test in the second quarter of 2010. Financial terms of the agreement were not disclosed.

24 Feb 2010

Idera Pharmaceuticals presents IMO-3100 TLR antagonist mechanism of action data at Keystone conference

Idera Pharmaceuticals, Inc. today presented data on the mechanism of action of IMO-3100, an antagonist of Toll-like Receptor (TLR) 7 and TLR9, in a preclinical primate model at the Keystone Symposia conference “Tolerance and Autoimmunity” being held February 21-26 in Taos, New Mexico. Idera is developing IMO-3100 for the treatment of autoimmune diseases. The presentation entitled “IMO-3100, a novel antagonist, suppresses TLR7- and TLR9-mediated immune responses in non-human primates” was made by Idera scientists.

24 Feb 2010

Gene expression in prostate cancer cell more complex than ever imagined

Scientists from Sydney's Garvan Institute of Medical Research have published a paper, online today in Nature Cell Biology, describing gene expression in a prostate cancer cell: more sweeping, more targeted and more complex than we could ever have imagined, even five years ago.

24 Feb 2010

Study may help in defining better therapeutic strategies for oral and throat cancer

Mayo Clinic researchers along with collaborators from Life Technologies are reporting on the application of a new approach for sequencing RNA to study cancer tumors. Their findings from a proof-of-principle study on oral carcinomas appear in the current issue of PLoS One, the online science journal.

24 Feb 2010

ViiV Healthcare highlights S/GSK1349572, SELZENTRY and EPZICOM for HIV/AIDS at 17th CROI

At the 17th Conference on Retroviruses and Opportunistic Infections (CROI), ViiV Healthcare presented new data across its broad range of investigational and current medicines for the treatment of HIV/AIDS. Highlighted data at the conference included an oral presentation on the investigational integrase inhibitor, S/GSK1349572, as well as data presentations on SELZENTRY® (maraviroc) and EPZICOM® (abacavir/lamivudine).

24 Feb 2010

FDA grants EUA for Longhorn Influenza A/H1N1-09 Prime RRT-PCR Assay in CLIA high complexity laboratories

Longhorn Vaccines & Diagnostics today announced it has been granted Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for its Longhorn Influenza A/H1N1-09 Prime RRT-PCR Assay™ in CLIA high complexity laboratories. . The Longhorn Influenza A/H1N1-09 Prime RRT-PCR Assay™ is a ready-use assay that requires no mixing prior to use and has been authorized for use on the ABI 7500.

24 Feb 2010

Pathogen study could provide new insights on gene regulation

About 50 percent of the world's population carry Helicobacter pylori (H. pylori) in their gastrointestinal tract - 30 percent of the German population are infected. Besides cancer, these bacteria are linked to other chronic diseases such as cardiovascular disease.

24 Feb 2010

ExonHit Therapeutics includes proprietary lead compounds into collaboration with Allergan

ExonHit Therapeutics today announced the inclusion of proprietary lead compounds, which were derived from one of its internal medicinal chemistry programs, into its productive and long-running strategic collaboration with Allergan.

23 Feb 2010

Scientists create tiny RNA molecule to synthesize proteins

An extremely small RNA molecule created by a University of Colorado at Boulder team can catalyze a key reaction needed to synthesize proteins, the building blocks of life. The findings could be a substantial step toward understanding "the very origin of Earthly life," the lead researcher contends.

23 Feb 2010

Medical test for aging adults could be helpful in determining infants’ intestinal conditions

A medical test initially researched for aging adults also could be helpful for premature babies, according to scientists with Texas AgriLife Research.

23 Feb 2010

Alnylam Pharmaceuticals initiates ALN-RSV01 Phase IIb trial in adult lung transplant patients for RSV infection

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has initiated a Phase IIb trial in adult lung transplant patients with ALN-RSV01, an RNAi therapeutic for the treatment of respiratory syncytial virus (RSV) infection. RSV infection in lung transplant patients represents an important unmet medical need; the condition is associated with significant morbidity, including the development of acute lung transplant rejection in 10% to 20% of infected patients.

22 Feb 2010

News outlets examine HIV vaccine research, cervical cancer screening data presented at conference

Several news outlets examine the latest reports out of this week's Conference on Retroviruses and Opportunistic Infections (CROI) in San Francisco.

20 Feb 2010

VIRxSYS announces results from prophylactic HIV vaccine study at 2010 CROI conference

VIRxSYS Corporation, a privately held company developing vaccines and RNA therapies for serious human diseases such as HIV and cardiovascular diseases, announced results from its prophylactic HIV vaccine (VRX1023) study in Rhesus Macaque monkeys during a presentation today at the 2010 Annual Conference on Retroviruses and Opportunistic Infections (CROI) in San Francisco, CA.

19 Feb 2010

PK/PD data demonstrates clear relationship between TBR-652 plasma concentrations and antiviral activity

Pharmacokinetic/pharmacodynamic (PK/PD) data for TBR-652, which is being developed by Tobira Therapeutics for the treatment of HIV infection, show a strong relationship between drug exposure and viral suppression with this next-generation CCR5 receptor antagonist. These data were presented here today at the 17th Conference on Retroviruses and Opportunistic Infections (CROI).

18 Feb 2010

Single microRNA exhibits potential to forecast outcomes of MPM

Rosetta Genomics, Ltd., a leading developer and provider of microRNA-based molecular diagnostics, announced today that the results of a joint study with the NYU Langone Medical Center were published online on February 16th, 2010, and are set to be published in the March 1st issue of the American Association for Cancer Research’s journal, Cancer Research.

18 Feb 2010

Norwegian government task force suggests formation of single company to commercialise biomaterial assets

Having studied the ethical, judicial and political arguments, the Norwegian government task force has suggested that a single nationwide company should be formed to commercialise biomaterials assets from the country’s various sources. The task force has also recommended HUNT Biosciences be a model for the national company.

18 Feb 2010

Gilead Sciences’ “Quad” regimen for HIV exhibits antiretroviral activity comparable to Atripla

Gilead Sciences, Inc. announced Phase II clinical trial results today showing that its investigational fixed-dose single-tablet “Quad” regimen of elvitegravir, GS 9350 (cobicistat) and Truvada® (emtricitabine and tenofovir disoproxil fumarate) for the treatment of HIV infection exhibited antiretroviral activity comparable to that of Atripla® (efavirenz 600 mg/ emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg).

18 Feb 2010

RNA News and Research

Further Reading

Regulus Therapeutics, GSK announce new collaboration on microRNA therapeutics targeting microRNA-122

α-defensins1-3 may be potential prophylactic agents in treatment of HIV / AIDS

Anadys Pharmaceuticals' ANA598 combination demonstrates 73% cEVR in ongoing Phase II study for HCV

Genetic test for autism: Transgenomic licenses exclusive intellectual property from IntegraGen

Idera Pharmaceuticals presents IMO-3100 TLR antagonist mechanism of action data at Keystone conference

Gene expression in prostate cancer cell more complex than ever imagined

Study may help in defining better therapeutic strategies for oral and throat cancer

ViiV Healthcare highlights S/GSK1349572, SELZENTRY and EPZICOM for HIV/AIDS at 17th CROI

FDA grants EUA for Longhorn Influenza A/H1N1-09 Prime RRT-PCR Assay in CLIA high complexity laboratories

Pathogen study could provide new insights on gene regulation

ExonHit Therapeutics includes proprietary lead compounds into collaboration with Allergan

Scientists create tiny RNA molecule to synthesize proteins

Medical test for aging adults could be helpful in determining infants’ intestinal conditions

Alnylam Pharmaceuticals initiates ALN-RSV01 Phase IIb trial in adult lung transplant patients for RSV infection

News outlets examine HIV vaccine research, cervical cancer screening data presented at conference

VIRxSYS announces results from prophylactic HIV vaccine study at 2010 CROI conference

PK/PD data demonstrates clear relationship between TBR-652 plasma concentrations and antiviral activity

Single microRNA exhibits potential to forecast outcomes of MPM

Norwegian government task force suggests formation of single company to commercialise biomaterial assets

Gilead Sciences’ “Quad” regimen for HIV exhibits antiretroviral activity comparable to Atripla

Industry Focus eBook - Neurology/Neuroscience - 2nd edition eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo